Search

Author/Creator Reyderman, Larisa

1. A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Issue 8 (2nd May 2018)

Authors:
Schafer, Eric S.; Rau, Rachel E.; Berg, Stacey; Liu, Xiaowei; Minard, Charles G.; D'Adamo, David; Scott, Rachael; Reyderman, Larisa; Martinez, Gresel; Devarajan, Sandhya; Reid, Joel M.; Fox, Elizabeth; Weigel, Brenda J.; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 65:Issue 8(2018)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users. Issue 4 (24th July 2022)

Authors:
Landry, Ishani; Hall, Nancy; Aluri, Jagadeesh; Filippov, Gleb; Reyderman, Larisa; Setnik, Beatrice; Henningfield, Jack; Moline, Margaret
Journal:
Journal of clinical psychopharmacology
Issue:
Volume 42:Issue 4(2022)
Page Start:
365
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users. Issue 4 (24th July 2022)

Authors:
Landry, Ishani; Hall, Nancy; Alur, Jagadeesh; Filippov, Gleb; Reyderman, Larisa; Setnik, Beatrice; Henningfield, Jack; Moline, Margaret
Journal:
Journal of clinical psychopharmacology
Issue:
Volume 42:Issue 4(2022)
Page Start:
374
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021)

Authors:
Lynch, Shau Yu; Irizarry, Michael C; Dhadda, Shobha; Li, David JianJun; Kanekiyo, Michio; Bogoslovsky, Tanya; Gee, Michelle; Reyderman, Larisa; Kaplow, June; Rabe, Martin; Hodgkinson, Mark; Kramer, Lynn D; Hampel, Harald; Swanson, Chad J
Journal:
Alzheimer's & dementia
Issue:
Volume 17(2021)Supplement 9
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Baseline regional Tau distribution predicts fast cognitive decline in subjects with mild cognitive impairment. (20th December 2022)

Authors:
Charil, Arnaud; Devanarayan, Viswanath; Murali, Leema; Qi, Xin; Krause, Stephen; Sachdev, Pallavi; Reyderman, Larisa; Koyama, Akihiko; Dhadda, Shobha; Irizarry, Michael C
Journal:
Alzheimer's & dementia
Issue:
Volume 18(2022)Supplement 5
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study. (June 2022)

Authors:
Landry, Ishani; Hall, Nancy; Aluri, Jagadeesh; Filippov, Gleb; Setnik, Beatrice; Dayal, Satish; Reyderman, Larisa; Moline, Margaret
Journal:
Journal of psychopharmacology
Issue:
Volume 36:Number 6(2022)
Page Start:
745
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers. Issue 3 (14th May 2013)

Authors:
Kosoglou, Teddy; Reyderman, Larisa; Tseng, Jack; Kumar, Bharath; Xuan, Fengjuan; Schiller, James; Meehan, Alan G.; Kim, Kenneth; Cutler, David L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 2:Issue 3(2013:Jul.)
Page Start:
223
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗